Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

Dihydroergotamine Mesylate

Known as: dihydroergotoxine mesylate, Methanesulfonate, Dihydroergotamine, Dihydroergotamine Methanesulfonate 
An ergot derivative with agonistic activity for alpha-adrenergic, serotonergic, and dopaminergic receptors. Dihydroergotamine mesylate most likely… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
Orally inhalable dihydroergotamine (iDHE), before the US Food and Drug Administration in 2013 for consideration for approval for… Expand
Review
2006
Review
2006
Dihydroergotamine mesylate (DHE), an ergot alkaloid, has been extensively utilized and studied in the treatment of episodic and… Expand
Review
2002
Review
2002
Migraine headache is a common disorder seen in primary care. It affects 18% of women and 6.5% of men in the United States, almost… Expand
Review
1997
Review
1997
Ergotamine tartrate (ET) and dihydroergotamine mesylate (DHE) have been widely and effectively used in the treatment of migraine… Expand
Highly Cited
1996
Highly Cited
1996
OBJECTIVE To assess the efficacy and tolerability of subcutaneous dihydroergotamine mesylate (DHE-45) vs subcutaneous sumatriptan… Expand
Highly Cited
1994
Highly Cited
1994
SYNOPSIS 
1992
1991
1991
Deep venous thrombosis and pulmonary emboli are reported to occur in up to 66% of the patients undergoing a major urological… Expand
Highly Cited
1981
Highly Cited
1981
ABSTRACT: Either supportive counseling (SC) or cognitive training (CT) was used in an attempt to enhance the efficiency of a… Expand
Highly Cited
1979
Highly Cited
1979
Randomized clinical trials in 300 patients undergoing major abdominal surgery or hip replacement arthroplasty were performed to… Expand